Advertisement

Neurological Sciences

, Volume 40, Issue 12, pp 2479–2489 | Cite as

The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: meta-analysis

  • Xiangming Wang
  • Yuehui Zhang
  • Chen Zhu
  • Guangzong Li
  • Jie Kang
  • Fang Chen
  • Ling YangEmail author
Review Article
  • 152 Downloads

Abstract

The main purpose of this study was to systematically evaluate the accuracy of neuromelanin-sensitive magnetic resonance imaging (NM-MRI) in Parkinson’s disease (PD) diagnosis using a meta-analysis method. In PubMed, Web of Science, Embase, and Google Scholar, the literatures were searched for the diagnostic value of neuromelanin-sensitive magnetic resonance imaging in PD. The literatures were screened in the light of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Data analysis was processed by Stata 12.0 software to obtain meta-analysis, heterogeneity analysis, and publication bias. Meta-analysis results showed by using NM-MRI observed substantia nigra pars compacta (SNpc) on PD, the pooled diagnostic sensitivity and specificity were 0.82 (95% CI, 0.74–0.87) and 0.82 (95% CI, 0.73–0.89), respectively. And the pooled positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 4.58 (95% CI, 3.08–6.82) and 0.22 (95% CI, 0.16–0.31), respectively. Moreover, subgroup analysis according to the measurement criteria of SNpc showed the SNpc volume should be used as good a marker for diagnosing PD. Finally, Fagan test demonstrated that when PLR was equal to 5, the posterior probability is significantly enhanced to 53%, compared with prior probability (20%). As for NLR (0.22), the prior probability is 20%, while the posterior probability remarkably dropped to 5%. In conclusion, SNpc signal detected by NM-MRI exhibited high sensitivity and specificity for diagnosis of PD, which was a high-performance imaging diagnostic method for PD. We recommend NM-MRI imaging technology to be widely used in Parkinson’s diagnosis.

Keywords

Parkinson’s disease Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) Meta-analysis Diagnostic method 

Notes

Compliance with ethical standards

The study was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The searched documents are gradually screened from the title, abstract, and full text according to the pre-set inclusion exclusion criteria. The two researchers conducted the same discussion at the same time. When there is controversy, it should be judged by the third researcher.

Conflict of interests

The authors declare they have no conflict of interests.

References

  1. 1.
    Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(Suppl 1):318–324CrossRefGoogle Scholar
  2. 2.
    Niu XL, Liu L, Song ZX, Li Q, Wang ZH, Zhang JL, Li HH (2016) Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease. J Neural Transm (Vienna) 123(12):1381–1386CrossRefGoogle Scholar
  3. 3.
    Zou YM, Liu J, Tian ZY, Lu D, Zhou YY (2015) Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1467–1472CrossRefGoogle Scholar
  4. 4.
    Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376CrossRefGoogle Scholar
  5. 5.
    Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134CrossRefGoogle Scholar
  6. 6.
    Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to disease and back. Physiol Rev 99(1):21–78CrossRefGoogle Scholar
  7. 7.
    Zucca FA, Vanna R, Cupaioli FA, Bellei C, de Palma A, di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Parkinsons Dis 4:17CrossRefGoogle Scholar
  8. 8.
    Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N (2018) Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 33(9):1488–1492CrossRefGoogle Scholar
  9. 9.
    Pavese N. 2018 Is neuromelanin the imaging biomarker for the early diagnosis of Parkinson’s disease that we were looking for? Parkinsonism Relat Disord. Google Scholar
  10. 10.
    Rovini E, Maremmani C, Moschetti A, Esposito D, Cavallo F (2018) Comparative motor pre-clinical assessment in Parkinson’s disease using supervised machine learning approaches. Ann Biomed Eng 46(12):2057–2068CrossRefGoogle Scholar
  11. 11.
    Zhang Z, Wang J, Chen S, Liu C, Zhang B, Peng R, Sun S, Sun X, Zhao G, Qu Q, Li Y, Zhu S, Pan X, Shao M, Wang Y (2018) Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Transl Neurodegener 7:32CrossRefGoogle Scholar
  12. 12.
    Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 quiz 1837CrossRefGoogle Scholar
  13. 13.
    Tarsy D, Gordon L 2012 Clinical diagnostic criteria for Parkinson’s disease. In: Parkinson’s disease. CRC Press, 732–741Google Scholar
  14. 14.
    Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601CrossRefGoogle Scholar
  15. 15.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Neurosurgery, Psychiatry. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefGoogle Scholar
  16. 16.
    El-Mewafy ZMH, Razek A, El-Eshmawy MM, El-Eneen NRA, El-Biaomy AAB (2018) Magnetic resonance spectroscopy of the frontal region in patients with metabolic syndrome: correlation with anthropometric measurement. Pol J Radiol 83:e215–e219CrossRefGoogle Scholar
  17. 17.
    El-Serougy L, Abdel Razek AA, Ezzat A, Eldawoody H, El-Morsy A (2016) Assessment of diffusion tensor imaging metrics in differentiating low-grade from high-grade gliomas. Neuroradiol J 29(5):400–407CrossRefGoogle Scholar
  18. 18.
    Razek AA, Elmongy A, Hazem M, Zakareyia S, Gabr W (2011) Idiopathic Parkinson disease effect of levodopa on apparent diffusion coefficient value of the brain. Acad Radiol 18(1):70–73CrossRefGoogle Scholar
  19. 19.
    Sasaki M, Shibata E, Kudo K, Tohyama K (2008) Neuromelanin-sensitive MRI. Clin Neuroradiol 18(3):147–153CrossRefGoogle Scholar
  20. 20.
    Xing Y, Sapuan A, Dineen RA, Auer DP (2018) Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov Disord 33(11):1792–1799CrossRefGoogle Scholar
  21. 21.
    Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, Filippi M (2010) Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 75(10):857–863CrossRefGoogle Scholar
  22. 22.
    Nakamura K, Sugaya K (2014) Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin. Neural Regen Res 9(7):759–760CrossRefGoogle Scholar
  23. 23.
    Hashido T, Saito S (2016) Quantitative T1, T2, and T2* mapping and semi-quantitative neuromelanin-sensitive magnetic resonance imaging of the human midbrain. PLoS One 11(10):e0165160CrossRefGoogle Scholar
  24. 24.
    Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, Tomimoto H (2013) Neuromelanin magnetic resonance imaging in Parkinson’s disease and multiple system atrophy. Eur Neurol 70(1–2):70–77CrossRefGoogle Scholar
  25. 25.
    Prasad S, Stezin A, Lenka A, George L, Saini J, Yadav R, Pal PK (2018) Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Eur J Neurol 25(4):680–686CrossRefGoogle Scholar
  26. 26.
    Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP (2017) In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology 283(3):789–798CrossRefGoogle Scholar
  27. 27.
    Kiebish MA, Narain NR (2019) Enabling biomarker discovery in Parkinson’s disease using multiomics: challenges, promise and the future. Per Med 16(1):5–7CrossRefGoogle Scholar
  28. 28.
    Zhang X, Gao F, Wang D, Li C, Fu Y, He W, Zhang J (2018) Tau pathology in Parkinson’s disease. Front Neurol 9:809CrossRefGoogle Scholar
  29. 29.
    Baquet ZC, Williams D, Brody J, Smeyne RJ (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161(4):1082–1090CrossRefGoogle Scholar
  30. 30.
    Yang J, Burciu RG, Vaillancourt DE (2018) Longitudinal progression markers of Parkinson’s disease: current view on structural imaging. Curr Neurol Neurosci Rep 18(12):83CrossRefGoogle Scholar
  31. 31.
    Knorle R (2018) Neuromelanin in Parkinson’s disease: from Fenton reaction to calcium signaling. Neurotox Res 33(2):515–522CrossRefGoogle Scholar
  32. 32.
    Matsuura K, Maeda M, Tabei KI, Umino M, Kajikawa H, Satoh M, Kida H, Tomimoto H (2016) A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci Lett 633:112–117CrossRefGoogle Scholar
  33. 33.
    Ohtsuka C, Sasaki M, Konno K, Koide M, Kato K, Takahashi J, Takahashi S, Kudo K, Yamashita F, Terayama Y (2013) Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541:93–98CrossRefGoogle Scholar
  34. 34.
    Reimao S, Pita Lobo P, Neutel D et al (2015) Quantitative analysis versus visual assessment of neuromelanin MR imaging for the diagnosis of Parkinson’s disease. J Park Dis 5(3):561–567Google Scholar
  35. 35.
    Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O et al (2015) Automated neuromelanin imaging as a diagnostic biomarker for Parkinson’s disease. Mov Disord 30(7):945–952CrossRefGoogle Scholar
  36. 36.
    Takahashi H, Watanabe Y, Tanaka H et al (2018) Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson’s disease. Br J Radiol 91(1086):20180037CrossRefGoogle Scholar
  37. 37.
    Isaias IU, Trujillo P, Summers P et al (2016) Neuromelanin imaging and dopaminergic loss in Parkinson’s disease. Front Aging Neurosci 8:196CrossRefGoogle Scholar
  38. 38.
    Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, Terae S, Nakanishi M, Shirato H (2013) 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology 55(6):719–724CrossRefGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019
corrected publication 2019

Authors and Affiliations

  1. 1.Department of NeurologyPanzhihua Central HospitalPanzhihua CityPeople’s Republic of China

Personalised recommendations